San Diego has spent decades quietly establishing itself as one of the world’s most influential biotechnology corridors.
From immunotherapy to precision medicine, some of oncology’s most important scientific advancements have emerged from Southern California’s expanding life sciences ecosystem. The region has become home to companies focused not only on developing new therapies but also on reshaping how cancer itself is treated.
Now, another oncology company may be positioning itself inside one of the industry’s most important evolving conversations.
Oncolytics Biotech (NASDAQ: NASDAQ) is part of a growing movement within oncology that no longer views cancer treatment through the narrow lens of isolated therapies alone. The future of immunotherapy appears to center on ecosystems, combination strategies, immune engagement, and therapies that improve the performance of existing treatments in difficult tumor settings.
That distinction may become increasingly important over the next decade.
For years, oncology development often revolved around a relatively straightforward objective: identify a therapy capable of generating strong standalone response activity and commercialize it as quickly as possible. While that approach still matters, the industry itself has evolved dramatically.
Checkpoint inhibitors transformed cancer treatment globally and helped redefine immunotherapy. At the same time, they also exposed one of oncology’s largest remaining challenges: many tumors still fail to generate sufficiently durable immune responses.
That reality has created an entirely new strategic race throughout oncology.
Today, large pharmaceutical companies are aggressively seeking platforms that can improve immune engagement, enhance durability, and enable therapies to function more effectively in combination-based treatment settings.
That shift helps explain why companies like Oncolytics are beginning to attract broader industry attention.
For years, the company’s lead asset, pelareorep, was often discussed primarily as a standalone therapeutic candidate. Today, the language surrounding the platform has evolved substantially.
The conversation now centers on immune engagement, durability, combination utility, regulatory pathways, manufacturing scalability, and how pelareorep may integrate into broader oncology treatment ecosystems that already generate billions of dollars annually.
And, importantly, the company’s optimism does not appear to be driven solely by theory.
According to Oncolytics’ clinical and translational findings from multiple studies, pelareorep has demonstrated evidence of interferon signaling, immune priming, T-cell activation, and broader modulation of the tumor microenvironment. More importantly, the company has generated survival observations across several difficult tumor settings simultaneously, including colorectal cancer, pancreatic cancer, and anal cancer.
That combination is becoming difficult for the industry to ignore. Especially by progressive pharmaceutical companies who rarely evaluate oncology platforms the same way public markets do.
It's not a secret: Wall Street often chases immediacy. Large pharma tends to evaluate durability.
That distinction matters enormously in immunotherapy.
In metastatic colorectal cancer, Oncolutics' REO 022 study evaluating pelareorep alongside FOLFIRI and bevacizumab demonstrated a median overall survival of 27 months, compared with a historical benchmark of roughly 11 months with standard treatment alone. Additional survival observations across pancreatic and anal cancer continue expanding the broader strategic discussion surrounding the platform.
According to the company, the FDA is more than listening. It's taking notice.
Management noted discussions that appear to reinforce the broader evolution occurring across oncology, particularly regarding the agency’s willingness to prioritize meaningful survival benefit even in situations where traditional response metrics may appear less dramatic.
Historically, those types of narrative shifts tend to attract serious industry attention.
And that may be where the Oncolytics story becomes particularly interesting from a market perspective. The company appears to be entering a very different operational phase than the one many stakeholders and observers still associate with the stock.
For years, Oncolytics focused heavily on validating the science and demonstrating pelareorep’s mechanism of action across multiple tumor settings. Today, the discussion has expanded toward registration-enabling studies, accelerated approval pathways, manufacturing readiness, commercialization strategy, and broader strategic positioning.
In other words, the company may no longer simply be trying to prove the platform works. It may now be positioning pelareorep for a much larger role inside the future of immunotherapy.
That evolution also aligns closely with the background of CEO Jared Kelly.
Before joining Oncolytics, Kelly helped guide Ambrx Biopharma through a strategic process that ultimately led to its multibillion-dollar acquisition by Johnson & Johnson. Prior to that transaction accelerating, Ambrx spent years developing beneath the radar of much of Wall Street despite building technology that later attracted enormous pharmaceutical interest.
Kelly now openly describes himself as a “transactional CEO,” a phrase rarely heard from biotechnology executives publicly. Yet the philosophy behind it may explain much of what is happening at Oncolytics today.
Rather than focusing exclusively on independently commercializing therapies across every indication over extremely long timelines, Kelly appears focused on building strategic platform value capable of attracting larger pharmaceutical infrastructure and accelerating global commercialization.
That means focusing not only on science, but also on scalability, regulatory clarity, operational execution, manufacturing readiness, and long-term positioning inside evolving oncology ecosystems.
And perhaps that is the larger story quietly developing around Oncolytics.
Because while much of the public market still appears to evaluate biotechnology companies through traditional standalone frameworks, the oncology industry itself may already be moving toward something far more collaborative.
The future of immunotherapy may not belong solely to individual therapies.
It may belong to the platforms that can help entire treatment ecosystems function better together.
Copyright © 2026 California Business Journal. All Rights Reserved.
For California Business Journal Disclaimers, go to /terms-conditions/.
